Abstract
dc:descriptionIdiopathic Membranous Glomerulopathy and its treatment have always been an enigma and a challenge for practicing nephrologists. Continuing efforts to explore this disease reveal potential pathways that might be involved in its pathogenesis and consequently its therapy. We describe two series of patients who received two different kinds of pharmacological agents relying on data reported in the literature. As we seek to investigate the possibility to exploit these agents in patients with MG, the primary goal in both cases was to evaluate their safety and tolerability profile. Subsequently, we assessed efficacy, if any, and the associated characteristics. i. Inhibition of Tumor Necrosis Factor Alpha (TNF-α) in idiopathic MGΝ Aim: To evaluate the safety, tolerability and potential efficacy of the TNF-α inhibitor, Etarnecept (ET), in patients with idiopathic Membranous Glomerulopathy. Patients-Methods: Patients with biopsy proven MGΝ, nephrotic range proteinuria and clearance of creatinine 50 ml/min or more were included in the study. Exclusion criteria were; treatment with steroids or cyclosporine during the previous 3 months, or cytotoxic agents within six months prior to entry. Etanercept was administered subcutaneously twice per week at a dose of 25 mg for 3 months. Plasma levels of TNF-α, interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL- 10), soluble intercellular adhesion molecule type 1 (sICAM-1), E-selectin, and the soluble form of tumor necrosis factor receptor-55 (sTNFR-55) were measured at the entry and at months 3, 6, and 9 post therapy start. Results: Twelve patients entered the study (4 females/8 males, mean time from diagnosis 8.3 months). The therapy was well tolerated; no infections or other adverse events were recorded by the end of follow up. Two patients exhibited complete -70- remission of proteinuria for at least four years. No significant change was found in the levels of TNF-α, IL-1, IL-6 IL-8 and IL-10 during the study. Similarly the levels of Eselectin and sICAM-1 were not significantly altered by therapy. Although we found no change in sTNFR-55 at 3 and 6 months, the levels of sTNFR-55 were found significantly decreased 9 months after therapy (mean difference from baseline: 334 ± 527pg/ml, p=0.028) ii. Depletion of B lymphocytes in idiopathic MGΝ Aim: To assess the potential therapeutic benefit of temporary depletion of B lymphocytes Rituximab in patients with idiopathic Membranous Glomerulopathy and describe any associated alterations in the subsets of lymphocytes. Patients-Methods: Patients were entered in the study if they had biopsy proven MG and no clinical or laboratory evidence of secondary causes of the disease. They should also have glomerular filtration rate above 30 ml/min/1.73m2, and minimum 24 hour proteinuria >3 g/day. Patients who had been treated with cyclosporine or cytotoxic agents the year prior to entry were excluded. Depletion of B cells was achieved with Rituximab, which was administered intravenously, in a dose of 375 mg/m2, once weekly, for 4 consecutive weeks. Partial remission was defined as a > 50% decrease in proteinuria and absolute proteinuria < 3 g/d while complete remission was defined as a >50% decrease in proteinuria and an absolute protein excretion< 0.3 gm/day.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lionaki, Sofia
- Λιονάκη, Σοφία
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19603